Christopher Gibson - 18 Feb 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Executive Officer, Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
18 Feb 2025
Transactions value $
-$182,284
Form type
4
Filing time
20 Feb 2025, 16:42:53 UTC
Previous filing
07 Feb 2025
Next filing
07 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Tax liability -$182K -17.1K -1.35% $10.64 1.26M 18 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RXRX Class B Common Stock 5.94M 18 Feb 2025 Class A Common Stock 0 $0.00 Direct F2
holding RXRX Class B Common Stock 486K 18 Feb 2025 Class A Common Stock 0 $0.00 by LAHWRAN-3 LLC F2, F3
holding RXRX Class B Common Stock 388K 18 Feb 2025 Class A Common Stock 0 $0.00 by LAHWRAN-4 LLC F2, F4
holding RXRX Class B Common Stock 67.9K 18 Feb 2025 Class A Common Stock 0 $0.00 by Gibson Family Trust F2, F5
holding RXRX Stock Option (Right to Buy) 1.05M 18 Feb 2025 Class A Common Stock 0 $7.25 Direct F6
holding RXRX Stock Option (Right to Buy) 667K 18 Feb 2025 Class A Common Stock 0 $10.09 Direct F7
holding RXRX Stock Option (Right to Buy) 814K 18 Feb 2025 Class A Common Stock 0 $8.55 Direct F8
holding RXRX Stock Option (Right to Buy) 399K 18 Feb 2025 Class A Common Stock 0 $11.40 Direct F9
holding RXRX Stock Option (Right to Buy) 5.44K 18 Feb 2025 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 283K 18 Feb 2025 Class A Common Stock 0 $2.48 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F3 The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F4 The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F5 The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
F6 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F7 The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F8 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F9 The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F10 The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.